$399.63
-0.47-0.12%
Last update: Nov 6, 7:48 PM
Madrigal Pharmaceuticals Inc
MDGLNASDAQ
Madrigal Pharmaceuticals (MDGL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.09 | $-2.32 | $-4.04 | $-0.52 |
| Actual | $1.83 | $-1.99 | $-3.25 | $-2.57 |
| Surprise | +267.9% | +14.2% | +19.6% | -394.2% |
| Revenue | ||||
| Estimate | $404.1M | $349.6M | $301.0M | $313.0M |
| Actual | $431.3M | $364.3M | $311.3M | $321.1M |
| Surprise | +6.72% | +4.18% | +3.44% | +2.58% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.08 | $-0.31 | $1.42 | $2.58 |
| Revenue | ||||
| Consensus | $475.8M | $458.4M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $1.83 | $-1.09 | 267.9 % |
| Q2 | Jul 30, 2026 | $-1.99 | $-2.32 | 14.2 % |
| Q1 | May 6, 2026 | $-3.25 | $-4.04 | 19.6 % |
| Q4 | Feb 19, 2026 | $-2.57 | $-0.52 | -394.2 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $431.27M | $404.10M | 6.72 % |
| Q2 | Jul 30, 2026 | $364.25M | $349.63M | 4.18 % |
| Q1 | May 6, 2026 | $311.34M | $300.97M | 3.44 % |
| Q4 | Feb 19, 2026 | $321.08M | $313.00M | 2.58 % |
